Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617429985> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2617429985 abstract "Background Omalizumab is a humanised monoclonal antibody manufactured by recombinant DNA technology. It is indicated as an add-on therapy to improve asthma control in patients with severe persistent allergic asthma with forced expiratory volume in 1 s(FEV1) Purpose To evaluate the effectiveness of omalizumab (Xolair) in asthmatic patients treated with this drug in a tertiary hospital during 2015. Material and methods This was an observational retrospective study of patients treated for asthma with omalizumab during 2015 in a tertiary hospital. Data were obtained by Farmatools and Drago AE programmes. All patients treated with omalizumab for at less 1 year were included. Clinical variables collected were: FEV1(RD >80%), serum total level of IgE (RD Results 66 patients were included in the study with a mean age of 37 years (40 women, 26 men). 94% of patients did not require emergency visits for asthma. At the start of the study, they presented mean serum levels of IgE of 1702 UI/mL; during this period, a mean decreased of 47% was observed. However, at the end of the study period, we observed increased serum levels of IgE in all patients. For FEV1, at the end of study, we found that: 17% of patients had FEV1 80% for the rest of the patients. As omalizumab is indicated in patients diagnosed with persistent allergic asthma, we should consider discontinuing treatment in patients with FEV1 Conclusion Omalizumab was highly effective in this study, similar or even better than the effectiveness showed in clinical trials. We observed that lower baseline total IgE was associated with less effective treatment. References and/or acknowledgements Technical data for omalizumab. No conflict of interest" @default.
- W2617429985 created "2017-06-05" @default.
- W2617429985 creator A5010396678 @default.
- W2617429985 creator A5025728177 @default.
- W2617429985 creator A5029135402 @default.
- W2617429985 creator A5033055030 @default.
- W2617429985 creator A5044472014 @default.
- W2617429985 creator A5053357163 @default.
- W2617429985 creator A5062012854 @default.
- W2617429985 date "2017-02-25" @default.
- W2617429985 modified "2023-10-17" @default.
- W2617429985 title "CP-018 Effectiveness of omalizumab in asthmatic patients" @default.
- W2617429985 doi "https://doi.org/10.1136/ejhpharm-2017-000640.17" @default.
- W2617429985 hasPublicationYear "2017" @default.
- W2617429985 type Work @default.
- W2617429985 sameAs 2617429985 @default.
- W2617429985 citedByCount "0" @default.
- W2617429985 crossrefType "proceedings-article" @default.
- W2617429985 hasAuthorship W2617429985A5010396678 @default.
- W2617429985 hasAuthorship W2617429985A5025728177 @default.
- W2617429985 hasAuthorship W2617429985A5029135402 @default.
- W2617429985 hasAuthorship W2617429985A5033055030 @default.
- W2617429985 hasAuthorship W2617429985A5044472014 @default.
- W2617429985 hasAuthorship W2617429985A5053357163 @default.
- W2617429985 hasAuthorship W2617429985A5062012854 @default.
- W2617429985 hasConcept C126322002 @default.
- W2617429985 hasConcept C141105273 @default.
- W2617429985 hasConcept C159654299 @default.
- W2617429985 hasConcept C167135981 @default.
- W2617429985 hasConcept C187212893 @default.
- W2617429985 hasConcept C203014093 @default.
- W2617429985 hasConcept C2776042228 @default.
- W2617429985 hasConcept C2778564945 @default.
- W2617429985 hasConcept C3020633164 @default.
- W2617429985 hasConcept C535046627 @default.
- W2617429985 hasConcept C71924100 @default.
- W2617429985 hasConceptScore W2617429985C126322002 @default.
- W2617429985 hasConceptScore W2617429985C141105273 @default.
- W2617429985 hasConceptScore W2617429985C159654299 @default.
- W2617429985 hasConceptScore W2617429985C167135981 @default.
- W2617429985 hasConceptScore W2617429985C187212893 @default.
- W2617429985 hasConceptScore W2617429985C203014093 @default.
- W2617429985 hasConceptScore W2617429985C2776042228 @default.
- W2617429985 hasConceptScore W2617429985C2778564945 @default.
- W2617429985 hasConceptScore W2617429985C3020633164 @default.
- W2617429985 hasConceptScore W2617429985C535046627 @default.
- W2617429985 hasConceptScore W2617429985C71924100 @default.
- W2617429985 hasLocation W26174299851 @default.
- W2617429985 hasOpenAccess W2617429985 @default.
- W2617429985 hasPrimaryLocation W26174299851 @default.
- W2617429985 hasRelatedWork W1925781980 @default.
- W2617429985 hasRelatedWork W1930827660 @default.
- W2617429985 hasRelatedWork W2017866305 @default.
- W2617429985 hasRelatedWork W2116250672 @default.
- W2617429985 hasRelatedWork W2397424022 @default.
- W2617429985 hasRelatedWork W2434377412 @default.
- W2617429985 hasRelatedWork W2516173034 @default.
- W2617429985 hasRelatedWork W2532769566 @default.
- W2617429985 hasRelatedWork W2550157314 @default.
- W2617429985 hasRelatedWork W2556304753 @default.
- W2617429985 hasRelatedWork W2761487814 @default.
- W2617429985 hasRelatedWork W2784312422 @default.
- W2617429985 hasRelatedWork W2791933168 @default.
- W2617429985 hasRelatedWork W2894920106 @default.
- W2617429985 hasRelatedWork W3022195529 @default.
- W2617429985 hasRelatedWork W3109667984 @default.
- W2617429985 hasRelatedWork W3111332292 @default.
- W2617429985 hasRelatedWork W3171092434 @default.
- W2617429985 hasRelatedWork W3193012657 @default.
- W2617429985 hasRelatedWork W3195546789 @default.
- W2617429985 isParatext "false" @default.
- W2617429985 isRetracted "false" @default.
- W2617429985 magId "2617429985" @default.
- W2617429985 workType "article" @default.